Back to search

Article

Doubtful Clinical Benefit of Casirivimab-Imdevimab Treatment for Disease Severity Outcome of High-Risk Patients with SARS-CoV-2 Delta Variant Infection

2022-01-31

Abstract excerpt

<h4>ABSTRACT</h4> Casirivimab/Imdevimab therapy reportedly retains neutralization potency against circulating SARS-CoV-2 variants, including Delta (B.1.617.2), but there are sparse data on its clinical benefit against the Delta variant among vaccinated and unvaccinated patients. We explored its therapeutic effect on COVID-19 severity outcome in terms of room air saturation <93% within 14 days of initial presentati...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
188ec7f9-9314-50ca-92ed-e5d65d7b9dc4
DOI
10.1101/2022.01.29.22270090
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Doubtful Clinical Benefit of Casirivimab-Imdevimab Treatment for Disease Severity Outcome of High-Risk Patients with SARS-CoV-2 Delta Variant InfectionDOI 10.1101/2022.01.29.22270090
EFFECTIVENESS OF CASIRIVIMAB-IMDEVIMAB AND SOTROVIMAB MONOCLONAL ANTIBODY TREATMENT AMONG HIGH-RISK PATIENTS WITH SARS-CoV-2 INFECTION: A REAL-WORLD EXPERIENCESemantic proximity
RECOMBINANT HUMAN MONOCLONAL ANTIBODIES CASIRIVIMAB/IMDEVIMAB USE IN INHIBITION OF THE SARS-CoV-2 VIRUS INFECTIONSemantic proximity
Real-world clinical outcomes of treatment with casirivimab-imdevimab among patients with mild-to-moderate coronavirus disease 2019 during the Delta variant pandemicSemantic proximity
Effectiveness of casirivimab and imdevimab, and sotrovimab during Delta variant surge: a prospective cohort study and comparative effectiveness randomized trialSemantic proximity
Clinical antiviral efficacy of remdesivir and casirivimab/imdevimab against the SARS-CoV-2 Delta and Omicron variantsSemantic proximity
Symptoms and severity in vaccinated and unvaccinated patients hospitalised with SARS-CoV-2 delta (B.1.617.2) variant infectionSemantic proximity
Effectiveness of REGEN-COV Antibody Combination in Preventing Severe COVID-19 OutcomesSemantic proximity
REGEN-COV antibody cocktail (casirivimab/imdevimab) for the treatment of inpatients with early hospital-acquired COVID-19: a single center experienceSemantic proximity
Clinical Severity and mRNA Vaccine Effectiveness for Omicron, Delta, and Alpha SARS-CoV-2 Variants in the United States: A Prospective Observational StudySemantic proximity
Real-World Effectiveness of Casirivimab and Imdevimab Among Patients Diagnosed With COVID-19 in the Ambulatory Setting: A Retrospective Cohort Study Using a Large Claims DatabaseSemantic proximity
Retrospective cohort study of the effectiveness of the Sputnik V and EpiVacCorona vaccines against the SARS-CoV-2 Delta variant in Moscow (June-July 2021)Semantic proximity
Clinical outcomes in vaccinated individuals hospitalized with Delta variant of SARS-CoV-2Semantic proximity
Select a neighboring publication to make it the new centre.